JPH05220216A - In vivo insertion tube - Google Patents
In vivo insertion tubeInfo
- Publication number
- JPH05220216A JPH05220216A JP4061209A JP6120992A JPH05220216A JP H05220216 A JPH05220216 A JP H05220216A JP 4061209 A JP4061209 A JP 4061209A JP 6120992 A JP6120992 A JP 6120992A JP H05220216 A JPH05220216 A JP H05220216A
- Authority
- JP
- Japan
- Prior art keywords
- tube
- antibacterial agent
- antibacterial
- vivo insertion
- insertion tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000003780 insertion Methods 0.000 title claims abstract description 34
- 230000037431 insertion Effects 0.000 title claims abstract description 34
- 238000001727 in vivo Methods 0.000 title abstract 6
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 31
- 230000002093 peripheral effect Effects 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 229910001410 inorganic ion Inorganic materials 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 3
- 229910052726 zirconium Inorganic materials 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 13
- 238000002845 discoloration Methods 0.000 abstract description 2
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 239000010410 layer Substances 0.000 description 8
- -1 silver ions Chemical class 0.000 description 8
- 239000004800 polyvinyl chloride Substances 0.000 description 6
- 229920000915 polyvinyl chloride Polymers 0.000 description 6
- 229920005989 resin Polymers 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229910052709 silver Inorganic materials 0.000 description 5
- 239000004332 silver Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 229910021536 Zeolite Inorganic materials 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000010457 zeolite Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- DCERVXIINVUMKU-UHFFFAOYSA-N diclofenac epolamine Chemical compound OCC[NH+]1CCCC1.[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCERVXIINVUMKU-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000001297 phlebitis Diseases 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- BJQHLKABXJIVAM-UHFFFAOYSA-N bis(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 239000004945 silicone rubber Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 229920002725 thermoplastic elastomer Polymers 0.000 description 1
- 229920005992 thermoplastic resin Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、体内挿入用チュ−ブ状
製品、例えばカテ−テルその他各種の医療用チュ−ブ類
に関するものである。更に詳しく述べれば、少くとも体
内に挿入される部位にわたり優れた抗菌性を発揮するこ
とができる熱可塑性樹脂又はゴムからなるカテ−テルも
しくは医療用チュ−ブ類に関するものである。前記各種
の医療用チュ−ブとは、消化管内チュ−ブ、口腔内チュ
−ブ、気管内チュ−ブ、胸腔内チュ−ブ、腹腔内チュ−
ブ、直腸内チュ−ブ、頭蓋内チュ−ブ等がある。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a tube-shaped product for insertion into a body, such as a catheter, and various medical tubes. More specifically, the present invention relates to a catheter or medical tube made of a thermoplastic resin or rubber capable of exerting an excellent antibacterial property at least at a site to be inserted into the body. The various medical tubes include digestive tract tube, intraoral tube, endotracheal tube, intrathoracic tube and intraperitoneal tube.
Tube, rectal tube, intracranial tube and the like.
【0002】[0002]
【従来技術及び発明が解決しようとする課題】近年、輸
液は電解質輸液から高カロリ−輸液まで適応が著しく拡
大して来ているが、それとともに副作用も増加してい
る。その中でカテ−テルに起因する合併症は挿入手技に
伴うものと留置、固定によるものに大別される。主な合
併症としては、静脈炎、細菌感染、カテ−テル塞栓があ
り、カテ−テルの長期留置は感染の危険性を多く含んで
いる。静脈炎が起こると穿刺部あるいは静脈に沿って発
赤、疼痛がみられ発熱を伴うことがあったり、細菌感染
により眼内炎や脳障害の副作用が発生することが知られ
ている。特に体内で感染巣がある場合、カテ−テル周辺
に新しい感染巣を作る。従来のカテ−テルはポリ塩化ビ
ニル、ポリウレタン等が主体となっているが、その一部
にウロキナ−ゼ等の抗血栓剤でコ−ティングしたものも
臨床評価されているが感染予防として完全なものとはな
っていない。BACKGROUND OF THE INVENTION In recent years, infusions have been remarkably expanded in applications from electrolyte infusions to high-calorie infusions, but side effects are also increasing. Among them, complications due to catheter are roughly classified into those associated with insertion procedure and those due to indwelling and fixation. The main complications are phlebitis, bacterial infection, and catheter embolism, and long-term catheter implantation involves many risks of infection. It is known that when phlebitis occurs, redness and pain may be observed along the puncture site or along the vein and fever may accompany, and side effects such as endophthalmitis and encephalopathy may occur due to bacterial infection. In particular, if there is an infection in the body, create a new infection around the catheter. Conventional catheters are mainly composed of polyvinyl chloride, polyurethane, etc., but some of them coated with antithrombotic agents such as urokinase have been clinically evaluated, but they are not completely effective for infection prevention. Not a thing.
【0003】従来の抗菌能の付与は、有機物質の抗菌剤
を化学結合させたり(特公平2−24544)、抗菌剤
を含有する被覆層を設ける(特公平3−27213)手
段があるが、抗菌剤は水溶性であるからいずれも基材か
ら体内に留置中に脱落してしまうという問題があった。
又無機物としては、銀、金、銅の直径約30ミクロン以
下の粒子として用いている例(特公平2−21269)
があるが、粒子が充分小さくなく均一に分散されず、又
懸濁液とした場合沈降してしまうという問題があった。
又銀イオンは反応し易く、直接に銀イオンを含有させる
と基材等と反応して、抗菌活性を失ってしまう等の問題
があった。また、銀ゼオライト系の抗菌剤はゼオライト
の有する結晶水が、加熱成形時に揮散し構造がこわれて
しまうので基材が変色してしまうという問題があった。
そこで、本発明者らは、以上の課題を解決するために鋭
意検討を重ねた結果次の発明に到達した。Conventionally, the antibacterial activity is imparted by means of chemically bonding an antibacterial agent of an organic substance (Japanese Patent Publication No. 24544) or providing a coating layer containing the antibacterial agent (Japanese Patent Publication No. 27213). Since the antibacterial agents are water-soluble, there is a problem that they fall off from the base material during the indwelling.
Further, as the inorganic substance, an example of using as particles of silver, gold or copper having a diameter of about 30 μm or less (Japanese Patent Publication No. 21269/1990).
However, there was a problem that the particles were not sufficiently small and were not uniformly dispersed, and when they were made into a suspension, they settled.
Further, silver ions are liable to react with each other, and when silver ions are directly contained, they react with a substrate or the like and lose antibacterial activity. Further, the silver zeolite-based antibacterial agent has a problem that the water of crystallization contained in the zeolite is volatilized during heat molding and the structure is broken, so that the base material is discolored.
Therefore, the inventors of the present invention have earnestly studied to solve the above problems, and have arrived at the next invention.
【0004】[0004]
【課題を解決するための手段】本発明は、少なくとも体
内挿入部位2に抗菌剤3を均一に混合したことを特徴と
する体内挿入用チュ−ブ1を提供する。また本発明は、
少なくとも体内挿入部位12の外周面及び/又は内周面
を抗菌剤含有層13で被覆したことを特徴とする体内挿
入用チュ−ブ11を提供する。DISCLOSURE OF THE INVENTION The present invention provides a tube 1 for insertion into a body characterized in that an antibacterial agent 3 is uniformly mixed at least in a body insertion site 2. Further, the present invention is
Provided is a tube 11 for insertion into a body, which is characterized in that at least an outer peripheral surface and / or an inner peripheral surface of a body insertion portion 12 is covered with an antibacterial agent-containing layer 13.
【0005】図1は、本発明の体内挿入用チュ−ブ1の
概略図である。体内挿入用チュ−ブ1は、例えばポリ塩
化ビニル樹脂、ポリエチレン、ポリウレタン等の熱可塑
性合成樹脂またはシリコ−ンゴム等の可撓性材料より構
成される。FIG. 1 is a schematic view of a tube 1 for insertion into the body of the present invention. The tube 1 for insertion into the body is composed of a thermoplastic synthetic resin such as polyvinyl chloride resin, polyethylene or polyurethane, or a flexible material such as silicone rubber.
【0006】体内挿入用チュ−ブ1は、体内挿入部位2
に抗菌剤3が均一に分散され混合されている。抗菌剤3
は、抗菌性無機微粉末が使用され、粒径が2ミクロン以
下の銀置換無機イオン交換体であって、無機イオンがジ
ルコニウム系のものが使用される。最も好ましい抗菌剤
として結晶水を含まない銀置換ジルコニウムイオン交換
体が使用される。The tube 1 for insertion into the body has an insertion site 2 inside the body.
The antibacterial agent 3 is uniformly dispersed and mixed therein. Antibacterial agent 3
Is an antibacterial inorganic fine powder, and is a silver-substituted inorganic ion exchanger having a particle size of 2 μm or less, and a zirconium-based inorganic ion is used. As the most preferable antibacterial agent, a silver-substituted zirconium ion exchanger containing no water of crystallization is used.
【0007】図2は、その他の体内挿入用チュ−ブ11
で、図3から図5は、図2のA部の拡大図である。体内
挿入用チュ−ブ11は図3に示すように抗菌剤を含有す
る層13(以下、抗菌剤含有層13)を体内挿入部位1
2の外周面に被覆したものである。FIG. 2 shows another tube 11 for insertion into the body.
3 to 5 are enlarged views of the portion A of FIG. As shown in FIG. 3, the tube 11 for insertion into the body has a layer 13 containing an antibacterial agent (hereinafter referred to as an antibacterial agent containing layer 13) which is inserted into the body 1
The outer peripheral surface of No. 2 is covered.
【0008】また、抗菌剤含有層13は、図4に示すよ
うに体内挿入部位12の内周面に形成しても良いし、図
5に示すように体内挿入部位12の外周面と内周面の両
方に形成することができる。The antimicrobial-containing layer 13 may be formed on the inner peripheral surface of the body insertion site 12 as shown in FIG. 4, or may be formed on the outer peripheral surface and the inner periphery of the body insertion site 12 as shown in FIG. It can be formed on both sides.
【0009】以上説明したように本発明の体内挿入用チ
ュ−ブ1、11では、抗菌剤3(抗菌剤含有層13に添
加されるものも含む)の粒径を2ミクロン以下とし、前
記可撓性の基材または抗菌剤含有層の中に均一に分散さ
せているので抗菌活性を長時間維持させることができ
る。また、結晶水を含まないジルコニウム系交換体を用
いることにより、従来の銀ゼオライト系の抗菌剤の結晶
水に起因する問題点は解決することができる。As described above, in the tubes 1 and 11 for insertion into the body of the present invention, the particle size of the antibacterial agent 3 (including those added to the antibacterial agent containing layer 13) is set to 2 μm or less, and Since it is uniformly dispersed in the flexible base material or the antibacterial agent-containing layer, the antibacterial activity can be maintained for a long time. Further, by using a zirconium-based exchanger that does not contain water of crystallization, the problems caused by the water of crystallization of conventional silver zeolite antibacterial agents can be solved.
【0010】[0010]
【実施例】実施例1 ポリ塩化ビニル樹脂(以下PVC)100重量部に対し
て表1の配合組成で、可塑剤(フタル酸ジオクチル、以
下DHEP)、エポキシ化大豆油、カルシウムステアレ
−ト、亜鉛ステアレ−トを配合し、さらに抗菌剤として
銀置換ジルコニウムイオン交換体を0.05、0.1、
0.5、2.0、4.0の各重量部添加して、ヘンシル
ミキサ−で混合し、押出機により170℃で内径3.0
mm×外径5.0mmのチュ−ブを15mm/minの
速度で成形した。 Example 1 A plasticizer (dioctyl phthalate, hereinafter DHEP), epoxidized soybean oil, calcium stearate, with the composition shown in Table 1 per 100 parts by weight of polyvinyl chloride resin (hereinafter PVC), Zinc stearate was added, and a silver-substituted zirconium ion exchanger was added as an antibacterial agent at 0.05, 0.1,
0.5, 2.0, and 4.0 parts by weight of each were added, mixed with a Hensyl mixer, and then an extruder with an inner diameter of 3.0 at 170 ° C.
A tube having an outer diameter of 5.0 mm and an outer diameter of 5.0 mm was molded at a speed of 15 mm / min.
【0011】[0011]
【表1】 配合組成 [Table 1] Composition
【0012】実施例2 ポリエチレン100重量部に銀置換ジルコニウムイオン
交換体を0.1、0.5、1.0、2.0、4.0の各
重量部をドライブレンドし、押出機を用いて200℃で
内径3.0mm×外径5.0mmのチュ−ブを成形し
た。 Example 2 100 parts by weight of polyethylene was dry-blended with 0.1 part, 0.5 part, 1.0 part, 2.0 part, and 4.0 part of a silver-substituted zirconium ion exchanger, and an extruder was used. At 200 ° C., a tube having an inner diameter of 3.0 mm and an outer diameter of 5.0 mm was molded.
【0013】実施例3 抗菌剤を添加しないで実施例1と同様にチュ−ブを作成
し、このチュ−ブをディッピング液(塩化ビニルぺ−ス
トレジン100重量部に対し、DHEP50重量部、カ
ルシウムステアレ−ト1重量部、亜鉛ステアレ−ト1重
量部、抗菌剤(銀置換ジルコニウムイオン交換体)を
0.1、0.5、1.0、2.0、4.0の各重量部を
混合し、脱泡して作成したもの)に浸漬し、引上げて1
20℃、10分間加熱硬化させて、抗菌剤層をチュ−ブ
表面に形成した。 Example 3 A tube was prepared in the same manner as in Example 1 without adding an antibacterial agent, and the tube was dipped into a dipping solution (100 parts by weight of vinyl chloride paste resin, 50 parts by weight of DHEP and calcium starch). 1 part by weight of allate, 1 part by weight of zinc stearate, and 0.1, 0.5, 1.0, 2.0, 4.0 parts by weight of antibacterial agent (silver-substituted zirconium ion exchanger). Mix, degas, and soak in), pull up to 1
The mixture was heated and cured at 20 ° C. for 10 minutes to form an antibacterial agent layer on the tube surface.
【0014】抗菌性の評価 実施例1で作成した各チュ−ブを切断して、加熱プレス
で5cm×5cmのシ−トを作成した。このシ−トに菌
液(大腸菌液、黄色ブドウ球菌液)0.2mlを接種
し、35℃で保存した後、生残菌を洗い出して、混釈平
板培養法により生菌数を測定し、シ−ト1枚あたりの生
菌数に換算した。その結果を表2に示す。 Evaluation of Antibacterial Property Each tube prepared in Example 1 was cut and a sheet of 5 cm × 5 cm was prepared by a heating press. 0.2 ml of bacterial solution (E. coli solution, Staphylococcus aureus solution) was inoculated into this sheet and stored at 35 ° C., after which surviving bacteria were washed out and the viable cell count was measured by the pour plate culture method. It was converted to the number of viable bacteria per sheet. The results are shown in Table 2.
【0015】[0015]
【表2】 [Table 2]
【0016】表2の結果により、ポリ塩化ビニル樹脂
に、抗菌剤を0.05重量部以上混合したものは、大腸
菌及び黄色ブドウ球菌に対し充分な抗菌性を示した。他
方、抗菌剤の添加量が0.05重量部未満では、充分な
抗菌性を示さず、5.0重量部を超えると、ポリ塩化ビ
ニル樹脂は、白色で不透明になるので好ましくない。抗
菌剤の添加量の好適な範囲は0.1〜4.0重量部であ
る。From the results shown in Table 2, the polyvinyl chloride resin mixed with 0.05 parts by weight or more of the antibacterial agent showed sufficient antibacterial activity against Escherichia coli and Staphylococcus aureus. On the other hand, if the amount of the antibacterial agent added is less than 0.05 parts by weight, sufficient antibacterial properties are not exhibited, and if it exceeds 5.0 parts by weight, the polyvinyl chloride resin becomes white and opaque, which is not preferable. The preferable range of the addition amount of the antibacterial agent is 0.1 to 4.0 parts by weight.
【0017】実施例2及び実施例3で作成したチュ−ブ
についても実施例1と同様に抗菌性評価を行ったところ
いずれのチュ−ブも抗菌剤の添加量が0.1〜4.0重
量部の範囲で充分な抗菌性を示すことが確認できた。The tubes prepared in Examples 2 and 3 were also evaluated for antibacterial properties in the same manner as in Example 1. In each tube, the amount of antibacterial agent added was 0.1 to 4.0. It was confirmed that sufficient antibacterial properties were exhibited in the range of parts by weight.
【0018】[0018]
【発明の効果】以上説明したように、本発明の体内挿入
用チュ−ブは、大腸菌及び黄色ブドウ球菌に対して充分
な抗菌性を示し、また基材変色等の問題もなく長時間一
定の状態を維持することができるので、衛生的で安心し
て治療に使用することができる。INDUSTRIAL APPLICABILITY As described above, the tube for insertion into the body of the present invention exhibits sufficient antibacterial activity against Escherichia coli and Staphylococcus aureus, and is constant for a long time without causing a problem such as discoloration of the substrate. Since the condition can be maintained, it can be used for treatment with hygiene and peace of mind.
【図1】本発明の体内挿入用チュ−ブの拡大断面図FIG. 1 is an enlarged sectional view of a tube for insertion into a body of the present invention.
【図2】本発明の体内挿入用チュ−ブの拡大断面図FIG. 2 is an enlarged sectional view of the tube for insertion into the body of the present invention.
【図3】図2のA部の拡大図3 is an enlarged view of part A of FIG.
【図4】図2のA部の拡大図FIG. 4 is an enlarged view of part A of FIG.
【図5】図2のA部の拡大図5 is an enlarged view of part A of FIG.
1、11 体内挿入用チュ−ブ 2、12 体内挿入部位 3 抗菌剤 13 抗菌剤含有層 1, 11 Tube for insertion into body 2, 12 Body insertion site 3 Antibacterial agent 13 Antibacterial agent-containing layer
───────────────────────────────────────────────────── フロントページの続き (72)発明者 五 島 弘 樹 大分県大野郡三重町大字玉田7番地の1 川澄化学工業株式会社三重工場内 ─────────────────────────────────────────────────── ─── Continuation of the front page (72) Inventor Hiroki Goshima 1-7 7 Tamada, Mie-machi, Ono-gun, Oita Prefecture Kawasumi Chemical Industry Co., Ltd. Mie factory
Claims (5)
一に混合したことを特徴とする体内挿入用チュ−ブ1。1. A tube 1 for insertion into a body, wherein an antibacterial agent 3 is uniformly mixed at least in a body insertion site 2.
/又は内周面を抗菌剤含有層13で被覆したことを特徴
とする体内挿入用チュ−ブ11。2. A tube 11 for insertion into a body, wherein at least the outer peripheral surface and / or the inner peripheral surface of the body insertion portion 12 is covered with an antibacterial agent-containing layer 13.
が、体内挿入用チュ−ブを構成する基材に対して0.0
5重量部から4.0重量部添加されてなることを特徴と
する体内挿入用チュ−ブ1(11)。3. The antibacterial agent according to claim 1 or 2 is used in an amount of 0.0 with respect to a base material constituting a tube for insertion into a body.
Tube 1 (11) for insertion into the body, characterized by being added from 5 parts by weight to 4.0 parts by weight.
が、粒径2ミクロン以下の銀置換無機イオン交換体であ
る体内挿入用チュ−ブ1(11)。4. A tube 1 (11) for insertion into a body, wherein the antibacterial agent according to any one of claims 1 to 3 is a silver-substituted inorganic ion exchanger having a particle size of 2 μm or less.
ニウム系である体内挿入用チュ−ブ1(11)。5. A tube 1 (11) for insertion into a body, wherein the inorganic ion exchanger according to claim 4 is a zirconium type.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4061209A JPH05220216A (en) | 1992-02-15 | 1992-02-15 | In vivo insertion tube |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4061209A JPH05220216A (en) | 1992-02-15 | 1992-02-15 | In vivo insertion tube |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05220216A true JPH05220216A (en) | 1993-08-31 |
Family
ID=13164579
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4061209A Pending JPH05220216A (en) | 1992-02-15 | 1992-02-15 | In vivo insertion tube |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH05220216A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006525089A (en) * | 2003-04-29 | 2006-11-09 | マリンクロット・インコーポレイテッド | Medical device with antibacterial layer |
JP2012532681A (en) * | 2009-07-09 | 2012-12-20 | ベクトン・ディキンソン・アンド・カンパニー | Antibacterial coating for invasive devices through the skin |
JP2017225831A (en) * | 2011-03-17 | 2017-12-28 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | High barrier elastomer fecal catheter or ostomy pouch |
-
1992
- 1992-02-15 JP JP4061209A patent/JPH05220216A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006525089A (en) * | 2003-04-29 | 2006-11-09 | マリンクロット・インコーポレイテッド | Medical device with antibacterial layer |
JP2012532681A (en) * | 2009-07-09 | 2012-12-20 | ベクトン・ディキンソン・アンド・カンパニー | Antibacterial coating for invasive devices through the skin |
JP2017225831A (en) * | 2011-03-17 | 2017-12-28 | コンバテック・テクノロジーズ・インコーポレイテッドConvatec Technologies Inc | High barrier elastomer fecal catheter or ostomy pouch |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU582796B2 (en) | Antimicrobial compositions | |
US4677143A (en) | Antimicrobial compositions | |
US7820284B2 (en) | Microbe-resistant medical device, microbe-resistant polymeric coating and methods for producing same | |
CA1224717A (en) | Antimicrobial compositions | |
US4592920A (en) | Method for the production of an antimicrobial catheter | |
US6267590B1 (en) | Antimicrobial dental products | |
KR940010079B1 (en) | Method of rendering a substrate surface antithrombogenic and/or anti-infective | |
US5236703A (en) | Polymeric substrates containing povidone-iodine as a control release biologically active agent | |
US8673441B2 (en) | Antimicrobial plastics product and process for production thereof | |
US5562652A (en) | Antiseptic medical apparatus | |
US20100068296A1 (en) | Methods for producing an anti-microbial plastic product | |
EP1786413B1 (en) | Antimicrobial elastomer composition and method for making | |
JPH0523790B2 (en) | ||
EP0952168A1 (en) | Graft polymer and moldings thereof for medical supply | |
EP0761243A1 (en) | Biostatic coatings and processes | |
JPH05220216A (en) | In vivo insertion tube | |
EP0887373A2 (en) | Antibacterial polymeric moldings | |
JPH0634817B2 (en) | Method for manufacturing antibacterial urinary catheter | |
JP3541627B2 (en) | Graft polymer and molded article for medical use using the same | |
JPH0474026B2 (en) | ||
JPH09135893A (en) | Antibacterial material and antibacterial molding using the same | |
JPH08156980A (en) | Container for eye lotion | |
JPH08141086A (en) | Trachea incision tube | |
JPH09135894A (en) | Antibacterial material and antibacterial molding using the same | |
MXPA96004622A (en) | Medical device antisept |